Additional Patients Support Clofarabine Promise; ILEX Oncology, Inc. (ILXO) Expects FDA Decision On NDA Filing By Year End
10/19/2005 5:12:23 PM
ILEX(TM) Oncology, Inc. (Nasdaq:ILXO) today announced that results were presented at the American Society of Hematology (ASH) 46th Annual Meeting and Exposition in San Diego of 19 additional patients to the pivotal Phase II clofarabine trials. These additional patient data support a 30 percent response rate, defined as complete remissions (CR), complete marrow remissions in the absence of platelet recovery (CRp) and partial remissions (PR), in children with refractory or relapsed acute lymphoblastic leukemia (ALL). In children with acute myeloid leukemia (AML) a 26 percent response rate was observed. This is the first update on clofarabine since a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) earlier this year.